4.8 Article

Engineering GPCR signaling pathways with RASSLs

Journal

NATURE METHODS
Volume 5, Issue 8, Pages 673-678

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nmeth.1232

Keywords

-

Funding

  1. NCRR NIH HHS [C06 RR018928] Funding Source: Medline
  2. NHLBI NIH HHS [R01 HL060664, R01 HL060664-10, HL60664-07, R01 HL060664-09, R01 HL060664-11, R01 HL060664-08] Funding Source: Medline
  3. NIDDK NIH HHS [R01 DK072071, R56 DK072071, DK072071] Funding Source: Medline
  4. NIMH NIH HHS [U19MH82441, U19 MH082441-020001, U19 MH082441, R01 MH061887] Funding Source: Medline

Ask authors/readers for more resources

We are creating families of designer G protein coupled receptors (GPCRs) to allow for precise spatiotemporal control of GPCR signaling in vivo. These engineered GPCRs, called receptors activated solely by synthetic ligands (RASSLs), are unresponsive to endogenous ligands but can be activated by nanomolar concentrations of pharmacologically inert, drug-like small molecules. Currently, RASSLs exist for the three major GPCR signaling pathways (G(s), G(i) and G(q)). We review these advances here to facilitate the use of these powerful and diverse tools.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available